Karyopharm Therapeutics Inc (KPTI)

May 04, 2026

Karyopharm (NASDAQ: KPTI) registers resale of 8.843M shares from private placement - Stock Titan

May 04, 2026

May 04, 2026

Karyopharm Therapeutics: Selling stockholder may resell up to 8,843,036 shares of Karyopharm common stockSEC filing - marketscreener.com

May 04, 2026

May 04, 2026

Karyopharm Therapeutics: Selling Stockholder May Resell Up To 8,843,036 Shares Of Karyopharm Common StockSEC Filing - TradingView

May 04, 2026

May 04, 2026

Karyopharm Therapeutics may offer up to $400 million in securitiesSEC filing - marketscreener.com

May 04, 2026

May 04, 2026

Karyopharm Therapeutics (NASDAQ: KPTI) files $400M shelf, $100M ATM with Jefferies - Stock Titan

May 04, 2026

May 04, 2026

Karyopharm (KPTI) Q1 2025 Earnings Transcript - AOL.com

May 04, 2026

Apr 29, 2026

Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN

Apr 29, 2026

Apr 29, 2026

KPTI stock down on mixed phase III myelofibrosis combo study data - MSN

Apr 29, 2026

Apr 29, 2026

KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN

Apr 29, 2026

Apr 29, 2026

Karyopharm Therapeutics (KPTI) price target increased by 13.33% to 13.87 - MSN

Apr 29, 2026

Apr 28, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 28, 2026

Apr 27, 2026

Piper Sandler Reiterates Overweight Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Apr 27, 2026

Apr 27, 2026

KPTI Upgraded by Piper Sandler -- Price Target Raised to $16.00 - GuruFocus

Apr 27, 2026

Apr 27, 2026

Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $16 - Moomoo

Apr 27, 2026

Apr 26, 2026

Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN

Apr 26, 2026

Apr 24, 2026

Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN

Apr 24, 2026

Apr 22, 2026

Is Karyopharm Therapeutics (KPTI) stock considered a safe play | Q4 2025: Below ExpectationsPricing Power - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 22, 2026

Karyopharm (KPTI) CMO logs pre-planned tax-related sale of 449 shares - Stock Titan

Apr 22, 2026

Apr 21, 2026

Karyopharm’s myelofibrosis trial selected for ASCO presentation By Investing.com - Investing.com Australia

Apr 21, 2026

Apr 21, 2026

Karyopharm’s myelofibrosis trial selected for ASCO presentation - Investing.com

Apr 21, 2026

Apr 21, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting - Karyopharm

Apr 21, 2026

Apr 21, 2026

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat

Apr 21, 2026

Apr 20, 2026

Is Karyopharm Therapeutics (KPTI) stock a smart investment today (Bullish Sentiment) 2026-04-20Risk Reward Ratio - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 17, 2026

RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance - Insider Monkey

Apr 17, 2026

Apr 16, 2026

KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 16, 2026

Apr 16, 2026

Karyopharm Therapeutics : Corporate Presentation - marketscreener.com

Apr 16, 2026